Wee Siong Chew1, Federico Torta2,3, Shanshan Ji3, Hyungwon Choi4,5,6, Husna Begum2,3, Xueling Sim4, Chin Meng Khoo5, Eric Yin Hao Khoo5, Wei-Yi Ong7, Rob M Van Dam4,5, Markus R Wenk2,3, E Shyong Tai4,5,8, Deron R Herr1,9. 1. Department of Pharmacology and. 2. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 3. Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, Singapore. 4. Saw Swee Hock School of Public Health, National University of Singapore, Singapore. 5. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National Health System, Singapore. 6. Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research, Singapore. 7. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 8. Duke-NUS Graduate Medical School, Singapore. 9. Department of Biology, San Diego State University, San Diego, California, USA.
Abstract
BACKGROUND: Sphingolipids (SPs) are ubiquitous, structurally diverse molecules that include ceramides, sphingomyelins, and sphingosines. They are involved in various pathologies including obesity and type 2 diabetes mellitus (T2DM). Therefore, it is likely that perturbations in plasma concentrations of SPs are associated with disease. Identifying these associations may reveal useful biomarkers or provide insight into disease processes. METHODS: We performed a lipidomics evaluation of molecularly-distinct SPs in the plasma of 2,302 ethnically-Chinese Singaporeans using electrospray ionization mass spectrometry coupled with liquid chromatography. SP profiles were compared to clinical and biochemical characteristics, and subjects were evaluated by follow-up visits for 11 years. RESULTS: We found that ceramides correlate positively but hexosylceramides correlate negatively with body mass index (BMI) and homeostatic model assessment of insulin resistance (HOMA-IR). Furthermore, SPs with a d16:1 sphingoid backbone correlate more positively with BMI and HOMA-IR, while d18:2 SPs correlate less positively, relative to canonical d18:1 SPs. We also found that higher concentrations of two distinct sphingomyelins were associated with a higher risk of T2DM (HR 1.45, 95% CI 1.18-1.78 for SM d16:1/C18:0; and HR 1.40, 95% CI 1.17-1.68 for SM d18:1/C18:0). CONCLUSION: We identified significant associations between SPs and obesity/T2DM characteristics, specifically, that of hexosylceramides, d16:1 SPs, and d18:2 SPs. This suggests that the balance of SP metabolism, rather than ceramide accumulation, is associated with the pathology of obesity. We further identified two specific SPs that may represent prognostic biomarkers for T2DM. FUNDING: Funding sources are listed in the Acknowledgements section.
BACKGROUND:Sphingolipids (SPs) are ubiquitous, structurally diverse molecules that include ceramides, sphingomyelins, and sphingosines. They are involved in various pathologies including obesity and type 2 diabetes mellitus (T2DM). Therefore, it is likely that perturbations in plasma concentrations of SPs are associated with disease. Identifying these associations may reveal useful biomarkers or provide insight into disease processes. METHODS: We performed a lipidomics evaluation of molecularly-distinct SPs in the plasma of 2,302 ethnically-Chinese Singaporeans using electrospray ionization mass spectrometry coupled with liquid chromatography. SP profiles were compared to clinical and biochemical characteristics, and subjects were evaluated by follow-up visits for 11 years. RESULTS: We found that ceramides correlate positively but hexosylceramides correlate negatively with body mass index (BMI) and homeostatic model assessment of insulin resistance (HOMA-IR). Furthermore, SPs with a d16:1 sphingoid backbone correlate more positively with BMI and HOMA-IR, while d18:2 SPs correlate less positively, relative to canonical d18:1 SPs. We also found that higher concentrations of two distinct sphingomyelins were associated with a higher risk of T2DM (HR 1.45, 95% CI 1.18-1.78 for SM d16:1/C18:0; and HR 1.40, 95% CI 1.17-1.68 for SM d18:1/C18:0). CONCLUSION: We identified significant associations between SPs and obesity/T2DM characteristics, specifically, that of hexosylceramides, d16:1 SPs, and d18:2 SPs. This suggests that the balance of SP metabolism, rather than ceramide accumulation, is associated with the pathology of obesity. We further identified two specific SPs that may represent prognostic biomarkers for T2DM. FUNDING: Funding sources are listed in the Acknowledgements section.
Authors: Jose Antonio Chavez; Trina A Knotts; Li-Ping Wang; Guibin Li; Rick T Dobrowsky; Gregory L Florant; Scott A Summers Journal: J Biol Chem Date: 2003-01-13 Impact factor: 5.157
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: M J Serlie; A J Meijer; J E Groener; M Duran; E Endert; E Fliers; J M Aerts; H P Sauerwein Journal: J Clin Endocrinol Metab Date: 2007-01-30 Impact factor: 5.958
Authors: Sekar Kathiresan; Olle Melander; Candace Guiducci; Aarti Surti; Noël P Burtt; Mark J Rieder; Gregory M Cooper; Charlotta Roos; Benjamin F Voight; Aki S Havulinna; Björn Wahlstrand; Thomas Hedner; Dolores Corella; E Shyong Tai; Jose M Ordovas; Göran Berglund; Erkki Vartiainen; Pekka Jousilahti; Bo Hedblad; Marja-Riitta Taskinen; Christopher Newton-Cheh; Veikko Salomaa; Leena Peltonen; Leif Groop; David M Altshuler; Marju Orho-Melander Journal: Nat Genet Date: 2008-01-13 Impact factor: 38.330
Authors: Johannes M Aerts; Roelof Ottenhoff; Andrew S Powlson; Aldo Grefhorst; Marco van Eijk; Peter F Dubbelhuis; Jan Aten; Folkert Kuipers; Mireille J Serlie; Tom Wennekes; Jaswinder K Sethi; Stephen O'Rahilly; Hermen S Overkleeft Journal: Diabetes Date: 2007-02-07 Impact factor: 9.461
Authors: Guanhong Miao; Ying Zhang; Zhiguang Huo; Wenjie Zeng; Jianhui Zhu; Jason G Umans; Gert Wohlgemuth; Diego Pedrosa; Brian DeFelice; Shelley A Cole; Amanda M Fretts; Elisa T Lee; Barbara V Howard; Oliver Fiehn; Jinying Zhao Journal: Diabetes Care Date: 2021-10-26 Impact factor: 19.112
Authors: Sona Rivas-Tumanyan; Lorena S Pacheco; Danielle E Haslam; Liming Liang; Katherine L Tucker; Kaumudi J Joshipura; Shilpa N Bhupathiraju Journal: Metabolites Date: 2022-06-02
Authors: Maria A Ahonen; Marcus Höring; Van Dien Nguyen; Sami Qadri; Juuso H Taskinen; Meghana Nagaraj; Martin Wabitsch; Pamela Fischer-Posovszky; You Zhou; Gerhard Liebisch; P A Nidhina Haridas; Hannele Yki-Järvinen; Vesa M Olkkonen Journal: Mol Med Date: 2022-06-17 Impact factor: 6.376
Authors: Guo-Chong Chen; Jin Choul Chai; Bing Yu; Gregory A Michelotti; Megan L Grove; Amanda M Fretts; Martha L Daviglus; Olga L Garcia-Bedoya; Bharat Thyagarajan; Neil Schneiderman; Jianwen Cai; Robert C Kaplan; Eric Boerwinkle; Qibin Qi Journal: Am J Clin Nutr Date: 2020-07-01 Impact factor: 7.045
Authors: Mathias Cardner; Mustafa Yalcinkaya; Sandra Goetze; Edlira Luca; Miroslav Balaz; Monika Hunjadi; Johannes Hartung; Andrej Shemet; Nicolle Kränkel; Silvija Radosavljevic; Michaela Keel; Alaa Othman; Gergely Karsai; Thorsten Hornemann; Manfred Claassen; Gerhard Liebisch; Erick Carreira; Andreas Ritsch; Ulf Landmesser; Jan Krützfeldt; Christian Wolfrum; Bernd Wollscheid; Niko Beerenwinkel; Lucia Rohrer; Arnold von Eckardstein Journal: JCI Insight Date: 2020-01-16
Authors: Kai Guo; Masha G Savelieff; Amy E Rumora; Fadhl M Alakwaa; Brian C Callaghan; Junguk Hur; Eva L Feldman Journal: J Clin Endocrinol Metab Date: 2022-03-24 Impact factor: 5.958
Authors: Sagar B Dugani; Luke R Christenson; Jeremiah A Aakre; Hai H Bui; Adrian Vella; Michelle M Mielke Journal: Diabetes Res Clin Pract Date: 2021-07-29 Impact factor: 8.180